Sarepta Therapeutics, Inc.

NASDAQ:SRPT

Biotechnology

Healthcare
$14.53 +1.71%

+$0.29 today

Market cap
$1.56B
Beta
0.20
P/E (TTM)
27.8
EPS (TTM)
$0.62
52W Low $10.42High $25.32

Volume 1.86M

Average 3.08M

SRPT Pre-Tax Margin

Income before tax as a percentage of revenue.

Sarepta Therapeutics, Inc.NASDAQ: SRPT

Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026

Pre-tax margin widens to 47.0%

Pre-tax margin was 47.0% in Q1 FY2026, up 98.4 pp from a year earlier. On a trailing-twelve-month basis it was 1.1%, up 8.5 pp year over year. Over 3 fiscal years it widened by 42.0 pp.

Context

  • Pre-tax margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
47.0%+109.8 pp QoQ
Last fiscal yearDec 2025
-31.9%-45.7 pp YoY
LTMMar 2026
1.1%+8.5 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+98.4 pp——
1 year-45.7 pp——
3 years+42.0 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-31.9%
Year-over-year change
-45.7pp

Pre-Tax Margin vs competitors

How SRPT compares with its peers on the latest reported figures

  • SRPT's LTM Mar 2026 pre-tax margin of 1.1% is the 2nd highest of the 6 companies compared; the peer median is -56.7%.
  • Its year-over-year change of +8.5 pp is the 3rd highest of 6, against a peer median of -29.9 pp.
  • Over three fiscal years its change of +42.0 pp compares with a peer median of +124.3 pp.
SRPT Competitors Peer median
Pre-Tax Margin for SRPT and competitors
Company Period LTM level YoY 3-year change
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 202616.6% +32.1 pp+117.3 pp
SRPTSarepta Therapeutics, Inc.LTM Mar 20261.1% +8.5 pp+42.0 pp
PTCTPTC Therapeutics, Inc.LTM Jun 2026-6.6% -44.4 pp+124.3 pp
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026-56.7% -29.9 pp+3.7 pp
WVEWave Life Sciences Ltd.LTM Mar 2026-255.7% -148.7 pp+3937.7 pp
NTLAIntellia Therapeutics, Inc.LTM Mar 2026-597.0% +557.1 pp+299.9 pp
DYNDyne Therapeutics, Inc.FY2025— ——
SLDBSolid Biosciences Inc.FY2025— ——
DSGNDesign Therapeutics, Inc.FY2025— ——
CAPRCapricor Therapeutics, Inc.FY2025— ——
PEPGPepGen Inc.FY2025— ——
Peer median (excluding SRPT) -56.7%-29.9 pp+124.3 pp

Competitors are the stored peer set for SRPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue701.89M933.01M1.24B1.9B2.2B
Cost of Revenue97.05M139.99M150.34M319.1M881.5M
Gross Profit604.84M793.02M1.09B1.58B1.32B
Gross Margin86.2%85.0%87.9%83.2%59.9%
Research & Development771.18M877.09M877.39M804.52M1.52B
Selling, General & Admin282.66M451.42M481.87M557.87M478.94M
Operating Expenses1.06B1.33B1.36B1.36B1.97B
Depreciation & Amortization38.02M41.86M44.4M37.72M44.52M
EBITDA(317.41M)(594.85M)(453.69M)316.89M(647.97M)
EBITDA Margin-45.2%-63.8%-36.5%16.7%-29.5%
Operating Income(459.71M)(536.2M)(267.82M)218.08M(657.77M)
Operating Margin-65.5%-57.5%-21.5%11.5%-29.9%
Interest Income511K27.72M85.97M71.77M19.57M
Interest Expense63.53M53.25M22.01M18.39M9.73M
Other Income / Expenses40.76M(153.76M)(252.27M)42.69M(44.45M)
Income Before Tax(418.95M)(689.96M)(520.1M)260.77M(702.23M)
Pre-Tax Margin-59.7%-73.9%-41.8%13.7%-31.9%
Income Tax Expense(168K)13.53M15.88M25.54M11.19M
Net Income(418.78M)(703.49M)(535.98M)235.24M(713.41M)
Net Margin-59.7%-75.4%-43.1%12.4%-32.5%
EPS (Basic)(5.15)(8.03)(5.80)2.47(7.13)
EPS (Diluted)(5.15)(8.03)(5.80)2.34(7.13)
Weighted Avg Shares81.26M87.56M92.4M95.08M104.79M
Weighted Avg Shares (Diluted)81.26M87.56M92.4M107.88M104.79M

Sarepta Therapeutics, Inc.

NASDAQ:SRPT

Intrinsic Alpha fair value

Locked

Current Price

$14.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.